Related characteristics and research progress of tumors affecting hypothalamic hormone secretion

doi:10.3877/cma.j.issn.2095-123X.2022.03.012

Abstract

Abstract:

Hypothalamus is the center of endocrine for human body, which is crucial to homeostasis and plays an irreplaceable role in regulating neuroendocrine function by secreting hypothalamic hormones. As the "initiator" of endocrine system, different functional areas of hypothalamus contain various neurosecretory cells responsible for the secretion of different hormones. Tumors of hypothalamic and adjacent tissue origin, including ganglion cell tumors, neuroblastomas, gliomas, malignant tumors and germ cell tumors, affect hormonal secretion in the hypothalamus or pituitary gland through occupying effects and abnormal secretion of hormones, resulting in a variety of complex clinical syndromes. In recent years there has been some research into tumors affecting hypothalamic hormone secretion, which is briefly reviewed here.

Key words: Hypothalamus, Tumors, Hormonal secretion, Treatment strategies

Tianshun Feng, Xianli Zhu, Shousen Wang. Related characteristics and research progress of tumors affecting hypothalamic hormone secretion[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(03): 183-186.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2022.03.012

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2022/V12/I03/183

References 29

[1]	Burbridge S, Stewart I, Placzek M. Development of the neuroendocrine hypothalamus[J]. Compr Physiol, 2016, 6(2): 623-643.
[2]	Asa SL, Ezzat S. Hypothalamic hormone-producing tumors[J]. Handb Clin Neurol, 2021, 181: 67-74.
[3]	Asa SL, Mete O. Hypothalamic endocrine tumors: an update[J]. J Clin Med, 2019, 8(10): 1741.
[4]	Lopes MB, Sloan E, Polder J. Mixed gangliocytoma-pituitary adenoma: insights on the pathogenesis of a rare sellar tumor[J]. Am J Surg Pathol, 2017, 41(5): 586-595.
[5]	Quiroga-Padilla PJ, González-Devia D, Andrade R, et al. Sellar gangliocytoma: case report and review of an extremely rare tumour[J]. Case Rep Neurol, 2021, 13(2): 475-482.
[6]	Donadille B, Villa C, Gaillard S, et al. Gangliocytoma: outcome of a rare silent pituitary tumour[J]. BMJ Case Rep, 2017: bcr2016218859.
[7]	Asa SL, Ezzat S. An update on pituitary neuroendocrine tumors leading to acromegaly and gigantism[J]. J Clin Med, 2021, 10(11): 2254.
[8]	Asa S, Ezzat S, Kelly D, et al. Hypothalamic vasopressin-producing tumors: often inappropriate diuresis but occasionally cushing disease[J]. Am J Surg Path, 2019, 43(2): 251-260.
[9]	Roper J, O’Carroll A, Young W, et al. The vasopressin Avpr1b receptor: molecular and pharmacological studies[J]. Stress, 2011, 14(1): 98-115.
[10]	Myung JK, Cho HJ, Park CK, et al. Clinicopathological and genetic characteristics of extraventricular neurocytomas[J]. Neuropathology, 2013, 33(2): 111-121.
[11]	Vincent JL, Su F. Physiology and pathophysiology of the vasopressinergic system[J]. Best Pract Res Clin Anaesthesiol, 2008, 22(2): 243-252.
[12]	Nakamura K, Kimura S, Yamazaki M, et al. Immunohistochemical analyses of thyroid-specific enhancer-binding protein in the fetal and adult rat hypothalami and pituitary glands[J]. Brain Res Dev Brain Res, 2001, 130(2): 159-166.
[13]	Zhang D, Kim SSR, Kelly DF, et al. Somatostatin receptor ligand therapy-a potential therapy for neurocytoma[J]. J Clin Endocrinol Metab, 2019, 104(6): 2395-2402.
[14]	Aihara Y, Chiba K, Eguchi S, et al. Pediatric optic pathway/hypothalamic glioma[J]. Neurol Med Chir (Tokyo), 2018, 58(1): 1-9.
[15]	Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1[J]. Nat Rev Dis Primers, 2017, 3: 17004.
[16]	Aslan IR, Cheung CC. Early and late endocrine effects in pediatric central nervous system diseases[J]. J Pediatr Rehabil Med, 2014, 7(4): 281-294.
[17]	Bizzarri C, Bottaro G. Endocrine implications of neurofibromatosis 1 in childhood[J]. Horm Res Paediatr, 2015, 83(4): 232-241.
[18]	Josefson J, Listernick R, Fangusaro JR, et al. Growth hormone excess in children with neurofibromatosis type 1-associated and sporadic optic pathway tumors[J]. J Pediatr, 2011, 158(3): 433-436.
[19]	廖指仪,田永吉.儿童视路胶质瘤诊疗和远期预后的研究进展[J].中华神经外科杂志, 2021, 37(2): 202-205.
[20]	Cohen NT, Cross JH, Arzimanoglou A, et al. Hypothalamic hamartomas: evolving understanding and management[J]. Neurology, 2021, 97(18): 864-873.
[21]	Harrison VS, Oatman O, Kerrigan JF. Hypothalamic hamartoma with epilepsy: review of endocrine comorbidity[J]. Epilepsia, 2017, 58 Suppl 2(Suppl 2): 50-59.
[22]	Bourdillon P, Ferrand-Sorbet S, Apra C, et al. Surgical treatment of hypothalamic hamartomas[J]. Neurosurg Rev, 2021, 44(2): 753-762.
[23]	van Tonder L, Burn S, Iyer A, et al. Open resection of hypothalamic hamartomas for intractable epilepsy revisited, using intraoperative MRI[J]. Childs Nerv Syst, 2018, 34(9): 1663-1673.
[24]	Ferrand-Sorbets S, Fohlen M, Delalande O, et al. Seizure outcome and prognostic factors for surgical management of hypothalamic hamartomas in children[J]. Seizure, 2020, 75: 28-33.
[25]	Boerwinkle VL, Foldes ST, Torrisi SJ, et al. Subcentimeter epilepsy surgery targets by resting state functional magnetic resonance imaging can improve outcomes in hypothalamic hamartoma[J]. Epilepsia, 2018, 59(12): 2284-2295.
[26]	Cantas-Orsdemir S, Eugster EA. Update on central precocious puberty: from etiologies to outcomes[J]. Expert Rev Endocrinol Metab, 2019, 14(2): 123-130.
[27]	Patti G, Ibba A, Morana G, et al. Central diabetes insipidus in children: diagnosis and management[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(5): 101440.
[28]	Das KK, Joseph J, Singh AK, et al. Capsuloganglionic germinoma: a rare site for uncommon childhood tumor[J]. Asian J Neurosurg, 2018, 13(2): 492-495.
[29]	Ilcus C, Silaghi H, Georgescu CE, et al. Molecular pathology and targeted therapies for personalized management of central nervous system germinoma[J]. J Pers Med, 2021, 11(7): 661.

Please choose a citation manager

Content to export